Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trialFlorence Ader, Raphaël Clère-Jehl, Gilles Peytavin et al.|The Lancet Infectious Diseases|2021Cited by 344
Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacyRaphaëlle Delattre, Laurent Debarbieux, Jérémy Seurat et al.|Cell Reports|2022Cited by 46
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohortSarah Tubiana, Catherine Chirouze, Charles Burdet et al.|Journal of Infection|2021Cited by 7
Combination of <i>in vivo</i> phage therapy data with <i>in silico</i> model highlights key parameters for treatment efficacyRaphaëlle Delattre, Laurent Debarbieux, Jérémy Seurat et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 0